Twist Bioscience Reports Executive Changes & Compensation on Jan 5
Ticker: TWST · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1581280
| Field | Detail |
|---|---|
| Company | Twist Bioscience Corp (TWST) |
| Form Type | 8-K |
| Filed Date | Jan 5, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $450,000, $195,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**TWST just announced executive changes and new compensation plans.**
AI Summary
Twist Bioscience Corp. filed an 8-K on January 5, 2024, to report the departure of a director or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for officers. This filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. This matters to investors because changes in leadership and executive compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting stock valuation.
Why It Matters
Changes in executive leadership and compensation can significantly influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company direction and performance, warranting a medium risk assessment.
Analyst Insight
Investors should monitor subsequent filings or company announcements for details on the specific individuals involved in the leadership changes and the nature of the compensatory arrangements to assess potential impacts on company strategy and financial outlook.
Key Players & Entities
- Twist Bioscience Corporation (company) — registrant
- The Nasdaq Global Select Market (company) — exchange where TWST is registered
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 5, 2024.
What specific items were disclosed in this 8-K filing by Twist Bioscience Corp.?
The 8-K filing disclosed information regarding the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
What is the trading symbol and exchange for Twist Bioscience Corporation's Common Stock?
Twist Bioscience Corporation's Common Stock trades under the symbol TWST on The Nasdaq Global Select Market.
What is the business address of Twist Bioscience Corporation?
The business address of Twist Bioscience Corporation is 681 Gateway Boulevard, South San Francisco, CA 94080.
What is the purpose of an 8-K filing?
An 8-K filing is a current report used to announce major events that shareholders should know about, such as changes in leadership, material agreements, or other significant corporate developments, as per Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,088 words · 4 min read · ~4 pages · Grade level 11.8 · Accepted 2024-01-05 08:08:19
Key Financial Figures
- $450,000 — s will receive an annual base salary of $450,000; a signing bonus of $195,000, subject t
- $195,000 — salary of $450,000; a signing bonus of $195,000, subject to repayment of the full gross
Filing Documents
- tm2333797d1_8k.htm (8-K) — 32KB
- tm2333797d1_ex99-1.htm (EX-99.1) — 11KB
- tm2333797d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-24-001628.txt ( ) — 225KB
- twst-20240105.xsd (EX-101.SCH) — 3KB
- twst-20240105_lab.xml (EX-101.LAB) — 33KB
- twst-20240105_pre.xml (EX-101.PRE) — 22KB
- tm2333797d1_8k_htm.xml (XML) — 3KB
01 Regulation FD
Item 7.01 Regulation FD . On January 5, 2024, the Company issued a press release announcing Mr. Laponis' appointment as Chief Financial Officer, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 7.01 and in the press release attached as Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall any such information or exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such document.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated January 5, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 5, 2024 Twist Bioscience Corporation /s/ Judy Yan Judy Yan Assistant General Counsel and Assistant Secretary